Saffron: Mood, Anxiety and Sleep
Saffron extract, made from the stigmas of the Crocus sativus flower, is sold for low mood and poor sleep. Pooled trials favour it on self-rated symptoms, but reviewers keep flagging publication bias, and many products do not match their labels.

Build your own printable peptide tracker
A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.
What Is Saffron and How Might It Work?
Saffron is the dried stigma of Crocus sativus. Its main bioactive components are crocins and safranal (affron mood trial, PMID 28735826), and a lab analysis of reference samples (dried saffron stigmas and the affron extract) found up to 17 crocins and crocetins plus picrocrocin and safranal (saffron supplement quality study, PMID 38002129).
A 2022 review of 414 research papers lists monoamine reuptake inhibition, NMDA receptor antagonism and GABA-α agonism as the main proposed antidepressant mechanisms, and says the mechanism, drug interactions and safety are not fully understood (saffron compounds review, PMID 36678554).
Results conflict. A 6-week French trial found no effect on inflammatory markers or HPA-axis (stress system) reactivity (subclinical mood trial, PMID 41047129). An 8-week Indian trial funded by its extract maker reported lower serum cortisol at days 28 and 56 (UO SAF 02 trial, PMID 42465135).
In a 52-person pilot of older adults with sleep complaints, 30 mg a day for four weeks improved self-rated and EEG-tracked sleep. In a subgroup of 26 whose gut bacteria were analysed, saffron raised several bacteria, including Faecalibacterium, Prevotella and Oscillibacter, with the authors noting a rise in short-chain-fatty-acid producers, and some shifts correlated with sleep measures (older-adult sleep pilot, PMID 40762630). This shows a correlation, not a cause.
What the Data Shows
Daily Dosing Schedule
Key Takeaways
- A 2026 meta-analysis of 34 randomized trials (1,769 people) found saffron lowered self-rated depression (BDI, 14 trials) by 4.39 points and self-rated anxiety (BAI, 6 trials) by 5.06 points, with moderate certainty (PMID 41693488).
- In the largest trial, 202 adults with low mood took 28 mg a day or placebo for 12 weeks; 72.3% on saffron vs 54.3% on placebo reached a clinically meaningful drop in depression score (PMID 40414301).
- In small 6-week trials, 30 mg of saffron a day showed no significant difference from fluoxetine in 40 outpatients with mild to moderate depression (PMID 15707766) or from citalopram in 66 patients with depression and anxious distress (PMID 27701683).
- Three placebo-controlled sleep trials point the same way: 14 mg twice daily improved insomnia scores in 63 adults (PMID 32056539), 20 or 30 mg cut insomnia symptoms in 165 adults (PMID 40698027), and 30 mg shortened tracker-measured sleep onset in 52 older adults (PMID 40762630). The first trial was funded by Pharmactive (PMID 32056539) and the second reports industry support from Activ'Inside (PMID 40698027).
- A 2020 meta-analysis of 12 studies found no significant difference in adverse effects between saffron and placebo, or between saffron and antidepressants (PMID 32221179).
- Product quality is uneven: of 17 saffron supplements analysed, 65% had contents that did not match the label, and some had undeclared additives or plant material other than saffron; two of its authors worked for the extract company Pharmactive (PMID 38002129).
- Whether clinicians would see the change. The 2026 meta-analysis found no significant effect on the clinician-rated HDRS or HARS scales (PMID 41693488), while the add-on trial found the reverse: a clinician-rated gain and no self-rated gain (PMID 31475623).
- How much of the pooled effect is real. A 2019 meta-analysis found evidence of publication bias and a lack of regional diversity (PMID 31135916), a 2021 meta-review said the saffron meta-analyses may have significant publication bias (PMID 33596697), and a 2013 meta-analysis asked for larger trials run outside Iran (PMID 24299602).
- Whether it helps people with only mild symptoms. A 6-week trial in 51 healthy adults found no effect on its main outcome (PMID 41047129), and a 22 mg daily dose did nothing in a 4-week trial of 128 adults (PMID 28735826).
- How independent the newer trials are. The largest trial lists two employees of the study sponsor, Pharmactive Biotech Products, as authors (PMID 40414301), and the funder helped design the women's trial (PMID 42389708).
- Whether it is safe in pregnancy. A 2026 review links higher doses or occupational exposure to uterine stimulation and a higher miscarriage risk (PMID 42186868).
- Long-term safety for mood use. The mood trials cited here ran 12 weeks at most (PMID 40414301, PMID 42389708); the one 12-month trial was in Alzheimer's disease and had no placebo group (PMID 25163440).
Frequently Asked Questions
Does saffron work for depression?
For self-rated symptoms, the pooled evidence says it may help. A 2026 meta-analysis of 34 trials found lower self-rated depression (BDI) scores, but no significant effect on the clinician-rated Hamilton scale (2026 GRADE meta-analysis, PMID 41693488). The 2022 WFSBP and CANMAT taskforce gave saffron a provisional recommendation for unipolar depression (WFSBP guideline, PMID 35311615). Reviewers have also flagged publication bias (2019 meta-analysis, PMID 31135916).
Does saffron help with anxiety?
Self-rated anxiety fell in pooled trials. Across six trials with 339 people, saffron lowered Beck Anxiety Inventory scores by 5.06 points, while the clinician-rated HARS showed no significant change (2026 GRADE meta-analysis, PMID 41693488). In 80 teenagers aged 12 to 16, 14 mg twice daily for 8 weeks improved self-reported anxiety, but parent reports were inconsistent (affron teen trial, PMID 29510352).
Does saffron help you sleep?
Three placebo-controlled trials report better sleep over four weeks. In 63 adults with poor sleep, 14 mg twice daily improved Insomnia Severity Index scores (affron sleep trial, PMID 32056539). In 165 adults with moderate insomnia, 20 or 30 mg a day reduced insomnia symptoms and stress (insomnia trial, PMID 40698027). In 52 older adults, 30 mg shortened sleep onset on an EEG tracker (older-adult sleep pilot, PMID 40762630).
How much saffron do studies use?
The trials cited here mostly gave 28 to 30 mg of extract a day. The affron trials used 28 mg (low-mood trial, PMID 40414301), often split as 14 mg twice daily (sleep trial, PMID 32056539; teen trial, PMID 29510352), and the head-to-head depression trials used 30 mg (fluoxetine comparison, PMID 15707766). In one 4-week trial, 28 mg a day improved mood scores and 22 mg a day did not (affron mood trial, PMID 28735826).
Is saffron safe to take?
At trial doses it was well tolerated in the studies here. A 2020 meta-analysis found no difference in adverse effects vs placebo (2020 meta-analysis, PMID 32221179). In a one-week test of 200 and 400 mg tablets, the 400 mg dose lowered standing systolic blood pressure, and some blood values shifted within normal ranges (safety study, PMID 18693099). A 2026 review links higher doses to miscarriage risk (pregnancy review, PMID 42186868).
Can saffron be taken with an antidepressant?
Some trials enrolled people already on one, under study supervision. In a trial of 160 adults on an antidepressant (139 analysed), 14 mg twice daily for 8 weeks improved clinician-rated depression scores (affron add-on trial, PMID 31475623). In men and women on fluoxetine, 30 mg a day for 4 weeks improved some sexual side effects, with side-effect rates similar to placebo (men's trial, PMID 22552758; women's trial, PMID 23280545). Ask your prescriber before combining them.
Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links support HighPeptides at no extra cost.
Related HighPeptides Research
Peer-Reviewed References
67-page guide: protocols, dosing, sourcing. Everything in one place.
Get the guide: $19 (normally $29) → The Peptide Buyer’s Playbook ($19) All ebooks & guides →Educational purposes only. Not medical advice.
Saffron extract is sold in the US as a dietary supplement, not an FDA-approved drug. Talk to a clinician before using it if you are pregnant, take prescription medicines such as antidepressants, or are being treated for depression or any other condition.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.